Rhyz Inc. (Nu Skin) Acquires BeautyBio

CurrentBody Acquires Tria Beauty

October 21, 2024

Consumer Products

CurrentBody has completed the acquisition of Tria Beauty, the pioneer in at‑home laser hair removal and skin rejuvenation devices. The purchase brings Tria into CurrentBody's Beauty Tech portfolio alongside CurrentBody Skin and ZIIP, expanding CurrentBody's capabilities in clinical-grade at‑home beauty technology.

American Exchange Group Acquires Urban Skin Rx

January 21, 2025

Consumer Products

American Exchange Group (AXNY Group) has acquired Urban Skin Rx, a clinical skincare brand focused on treatments for diverse skin tones. The acquisition expands AXNY's beauty and personal care portfolio and aims to grow Urban Skin Rx's direct-to-consumer business, product range, and global retail presence.

BioIVT Acquires ZenBio

August 21, 2024

Healthcare Services

BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.

MJH Life Sciences Acquires NewBeauty from SANDOW Media

May 6, 2025

Media & Entertainment

MJH Life Sciences has acquired NewBeauty, the beauty-focused media brand, from SANDOW Media. The acquisition expands MJH's footprint in beauty and aesthetics by combining NewBeauty's consumer and professional editorial platforms with MJH's clinical and specialty-media capabilities.

L'Oréal Acquires Skinbetter Science

September 23, 2022

Consumer Products

L'Oréal has signed an agreement to acquire Skinbetter Science, a physician-dispensed U.S. skincare brand known for dermatology-backed, clinical formulations. Skinbetter Science—headquartered in Phoenix, Arizona and reporting nearly $95 million in trailing‑12‑month sales to August 31, 2022—will be integrated into L'Oréal USA's Active Cosmetics Division while its leadership team remains in place.

Bristol Myers Squibb Acquires RayzeBio for Approximately $4.1 Billion

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire radiopharmaceutical developer RayzeBio in an all-cash tender offer of $62.50 per share, valuing RayzeBio at approximately $4.1 billion (about $3.6 billion net of cash). The acquisition brings RayzeBio's actinium-based radiopharmaceutical platform, a Phase 3 lead program (RYZ101) and in-house radiopharmaceutical manufacturing capabilities into Bristol Myers Squibb's oncology franchise to accelerate development and commercialization of targeted radiopharmaceutical therapeutics.